Eric Schadt, PhD is founder and CEO of Sema4, a patient-centered health intelligence company built on the idea that more information, deeper analysis, and increased longitudinal engagement of patients will improve the diagnosis, treatment, and prevention of disease. Eric has overseen rapid growth at Sema4 since the company was founded in 2017, driven by the company’s dedication to advancing healthcare through data-driven insights.
Eric is a world-renowned expert on constructing predictive models of disease that link molecular biology to physiology to enable clinical medicine. Over the past 20 years, he has built groups and companies (Merck, Rosetta, Sage Bionetworks, Pacific Biosciences, Icahn Institute, and now Sema4) to elucidate the complexity of human diseases. He has published more than 400 peer-reviewed papers in leading scientific journals and contributed to discoveries relating to the genetic basis of common human diseases such as diabetes, obesity, and Alzheimer’s disease. Now, with Centrellis®, Sema4’s innovative health intelligence platform, Eric is using advanced network analysis to build better models of human health and deliver personalized insights for patients.
Eric also serves as the Dean for Precision Medicine and Mount Sinai Professor in Predictive Health and Computational Biology at Icahn School of Medicine at Mount Sinai. He was previously Founding Director of Icahn Institute for Genomics and Multiscale Biology, and Professor and Chair of the Department of Genetics and Genomic Sciences.
Eric earned his PhD from the University of California, Los Angeles, his MA from the University of California, Davis, and his BS from California Polytechnic State University-San Luis Obispo.
What is Eric Schadt's net worth?
The estimated net worth of Eric Schadt is at least $87,172.50 as of May 20th, 2022. Dr. Schadt owns 7,375 shares of GeneDx stock worth more than $87,173 as of April 25th. This net worth approximation does not reflect any other assets that Dr. Schadt may own. Learn More about Eric Schadt's net worth.
How do I contact Eric Schadt?
Has Eric Schadt been buying or selling shares of GeneDx?
Eric Schadt has not been actively trading shares of GeneDx within the last three months. Most recently, on Friday, May 20th, Eric Schadt bought 3,030 shares of GeneDx stock. The stock was acquired at an average cost of $63.36 per share, with a total value of $191,980.80. Following the completion of the transaction, the insider now directly owns 7,375 shares of the company's stock, valued at $467,280. Learn More on Eric Schadt's trading history.
Who are GeneDx's active insiders?
Are insiders buying or selling shares of GeneDx?
In the last year, GeneDx insiders bought shares 5 times. They purchased a total of 116,742 shares worth more than $491,562.34. In the last year, insiders at the sold shares 32 times. They sold a total of 78,286 shares worth more than $445,847.63. The most recent insider tranaction occured on March, 18th when CEO Katherine Stueland sold 8,559 shares worth more than $90,639.81. Insiders at GeneDx own 28.1% of the company.
Learn More about insider trades at GeneDx. Information on this page was last updated on 3/18/2024.
